Hematologic Malignancy
Cutaneous Lymphoma
CI-CAN-00000792Explore in graph →
Hematologic69 active trials10 approved drugs
- NCIt
- C171101
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000792Explore in graph →
Clinical trials
360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (77)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07710781 | Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies | not yet recruiting | N/A | 300 | Ossium Health, Inc.INDUSTRY | 0 | Sep 10, 2026 | clinicaltrials |
| NCT07758491 | A Phase I/II Study of FG-M131 in TRBC1+ Relapsed/Refractory Peripheral T-Cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 110 | FutureGen Biopharmaceutical (Beijing) Co., LtdINDUSTRY | 1 | Sep 2, 2026 |
| clinicaltrials |
| NCT07781449 | Topical JAK-Inhibition of Early-Stage CTCL | not yet recruiting | Phase 2 | 15 | Aarhus University HospitalOTHER | 0 | Aug 26, 2026 | clinicaltrials |
| NCT07717580 | Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL)(BV-LISA-CTCL) | not yet recruiting | Phase 2 | 46 | Peking University First HospitalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07714187 | A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides | not yet recruiting | Phase 1 | 30 | SecuraBioINDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07691450 | Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma | not yet recruiting | Phase 1 | 40 | City of Hope Medical CenterOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07658924 | Efficacy and Safety of Benvitimod Cream in Cutaneous T-Cell Lymphoma(BEST-CTCL) | not yet recruiting | Phase 2 | 35 | Peking University First HospitalOTHER | 0 | Jun 22, 2026 | clinicaltrials |
| NCT07608549 | FLASH Pilot Phase 1 Safety Study | not yet recruiting | N/A | 10 | Lesley A. JarvisOTHER | 0 | May 27, 2026 | clinicaltrials |
| NCT05728879 | Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution | not yet recruiting | Early Phase 1 | 30 | Northwestern UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07535710 | Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 37 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07529405 | A Study of VG712 in Patients With Mycosis Fungoides(CurbMF) | not yet recruiting | Phase 2 | 386 | Virogen Biotechnology Inc.INDUSTRY | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07213882 | A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)(CITY) | not yet recruiting | Early Phase 1 | 30 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Oct 9, 2025 | clinicaltrials |
| NCT07178457 | Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance(BeCALM) | not yet recruiting | Phase 3 | 84 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Sep 17, 2025 | clinicaltrials |
| NCT06385522 | A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System | not yet recruiting | Phase 1 | 37 | Boston Immune Technologies and TherapeuticsINDUSTRY | 0 | Jul 8, 2025 | clinicaltrials |
| NCT07046663 | Long-term Assessment of Chlormethine Gel in Mycosis Fungoides(FIL_CLOR-CTCL) | not yet recruiting | — | 190 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT06651203 | Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter Study(KISS01) | not yet recruiting | — | 460 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Oct 21, 2024 | clinicaltrials |
| NCT05205902 | TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides(TOTEM-01) | not yet recruiting | Phase 3 | 78 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Jan 25, 2022 | clinicaltrials |
| NCT04520529 | Identification of Prognostic Factors and New Therapeutic Targets in Cutaneous Lymphomas(LYMPHOTEQ) | not yet recruiting | N/A | 500 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Aug 20, 2020 | clinicaltrials |
Data updated 20 days agoSource updated Sep 10, 2026source: clinicaltrials